CaronAlyceJacobsonMD

Oncology • Boston, MA

Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Jacobson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jacobson's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3779

Fax+1 617-632-5822

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2004 - 2007
Columbia University Vagelos College of Physicians and SurgeonsClass of 2004

Certifications & Licensure

CT State Medical License 2013 - 2025
MA State Medical License 2008 - 2025
NY State Medical License 2006 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
Completed
Phase 1
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma Start of enrollment: 2014 Dec 01
Completed
Phase 2
RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA Start of enrollment: 2018 Oct 30
Active, not recruiting
Phase 1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma Start of enrollment: 2018 Nov 20
Terminated
Phase 1
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Start of enrollment: 2020 Oct 05
Active, not recruiting
Phase 2
Axi-cel in CNS Lymphoma Start of enrollment: 2020 Dec 04
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

239 citations
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos
Blood Advances. 2020-10-13
100 citations
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Nicholas J Haradhvala, Mark B Leick, Katie Maurer, Satyen H Gohil, Rebecca C Larson
Nature Medicine. 2022-09-01
6 citations
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.
Hazim S Ababneh, Andrea K Ng, Matthew J Frigault, Jeremy S Abramson, Patrick Connor Johnson
Haematologica. 2023-11-01

Journal Articles

Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-cell Therapy
Sarah Nikiforow, Caron Jacobson, JAMA Neurology

Abstracts/Posters

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Caron A. Jacobson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Indolent Lymphomas: The Marathon Has a New Course
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS LymphomaDecember 13th, 2022
$Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data from Pivotal Study Showing Durable Long-Term Survival in Patients with Refractory Large B-cell Lymphoma$
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data from Pivotal Study Showing Durable Long-Term Survival in Patients with Refractory Large B-cell LymphomaDecember 11th, 2021
$Longer-Term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement over Current Therapies in Comparative Analysis$
Longer-Term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement over Current Therapies in Comparative AnalysisJune 12th, 2021
Join now to see all